# Xanthomicrol

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/xanthomicrol
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-05
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** 5,7-dihydroxy-6,8-dimethyl-2-(4-hydroxyphenyl)-4H-chromen-4-one, Dracocephalum kotschyi flavone, 6,8-dimethyl-5,7,4'-trihydroxyflavone, Xanthomicrol flavone

## Overview

Xanthomicrol is a polymethoxylated flavonoid found primarily in Satureja species and Calamintha incana that exerts anticancer effects by inhibiting angiogenesis, inducing apoptosis, and arresting cell cycle progression at the G2/M checkpoint. Its primary mechanisms involve suppression of VEGF-driven neovascularization and activation of caspase-dependent cell death pathways in malignant cell lines.

## Health Benefits

• Inhibits angiogenesis and tumor growth in vivo, showing antiangiogenic effects comparable to thalidomide [1]. • Induces apoptosis and G2/M cell cycle arrest in HCT116 colon cancer cells [2]. • Demonstrates cytotoxicity in HeLa cells while being selective over normal fibroblasts [3]. • Suppresses proliferation and invasion in triple-negative breast cancer models [7]. • Reduces migration in hepatocellular carcinoma cells [9].

## Mechanism of Action

Xanthomicrol suppresses angiogenesis by inhibiting VEGF receptor signaling, reducing endothelial cell proliferation and tube formation comparably to thalidomide in vivo models. In HCT116 colon cancer cells, it activates the intrinsic apoptotic pathway through caspase-3 and caspase-9 cleavage while simultaneously inducing G2/M cell cycle arrest, likely via downregulation of cyclin B1 and CDK1 activity. Its selective cytotoxicity in HeLa cervical cancer cells over normal fibroblasts suggests partial targeting of cancer-specific survival pathways, potentially involving suppression of [NF-κB](/ingredients/condition/inflammation) or PI3K/Akt signaling.

## Clinical Summary

Research on xanthomicrol remains entirely preclinical, with no published human clinical trials as of 2024. In vitro studies using HCT116 colon cancer and HeLa cervical cancer cell lines have demonstrated dose-dependent cytotoxicity and apoptosis induction, though specific IC50 values vary by model. In vivo murine models of angiogenesis showed antiangiogenic effects comparable to thalidomide, a clinically used reference compound, lending biological plausibility to the findings. The overall evidence base is preliminary; efficacy and safety in humans have not been established, and extrapolation from cell and animal studies should be made with caution.

## Nutritional Profile

Xanthomicrol (5,4'-dihydroxy-6,7,8-trimethoxyflavone; C₁₈H₁₆O₇; MW ~344.32 g/mol) is a polymethoxylated flavone, not a nutritional macronutrient source. It is a specialized bioactive secondary metabolite found in select Lamiaceae species. Key details: • Primary natural sources: Aerial parts of Dracocephalum kotschyi (Iranian dragonhead), Orthodon dianthera, and certain Salvia species. Concentrations in dried plant material are typically low, estimated in the range of 0.01–0.5% w/w depending on plant part, chemotype, and extraction method. • Chemical class: Polymethoxylated flavone with three methoxy groups at C-6, C-7, and C-8, and hydroxyl groups at C-5 and C-4'. This high degree of methoxylation increases lipophilicity (estimated LogP ~2.5–3.0) relative to unmethylated flavones, which may enhance passive intestinal absorption and metabolic stability compared to polyhydroxylated analogs. • Bioavailability notes: No dedicated human pharmacokinetic studies are available. Based on structural analogy to other polymethoxylated flavones (e.g., nobiletin, tangeretin), oral bioavailability is expected to be modest but improved over hydroxylated flavones due to resistance to Phase II conjugation (glucuronidation/sulfation). Lipophilic formulation or co-administration with dietary fats may enhance absorption. Hepatic CYP450-mediated O-demethylation is a likely primary metabolic route, potentially generating active hydroxylated metabolites. • It provides negligible calories, protein, fat, carbohydrate, fiber, vitamins, or minerals at pharmacologically relevant doses (typically studied in vitro at 5–100 µM; in vivo rodent studies use doses in the range of 25–200 mg/kg). • Co-occurring bioactives in source plants: Dracocephalum kotschyi extracts also contain calycopterin, cirsimaritin, isokaempferide, luteolin, and rosmarinic acid, which may contribute to synergistic biological effects observed with crude extracts versus isolated xanthomicrol. • No established Dietary Reference Intake (DRI), Recommended Daily Allowance (RDA), or tolerable upper intake level exists for xanthomicrol. It is classified as a phytochemical research compound rather than a nutrient.

## Dosage & Preparation

Preclinical studies used an intraperitoneal dosage of 50 mg/kg daily in mice for 21 days. In vitro studies applied concentrations ranging from 15-200 μM, depending on the cell line. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

No human safety data, toxicology studies, or established safe dosage ranges exist for xanthomicrol supplementation. Given its potent pro-apoptotic and antiangiogenic activity demonstrated in cell models, theoretical interactions with anticoagulants, chemotherapy agents, or antiangiogenic drugs such as bevacizumab cannot be excluded. Pregnant or breastfeeding individuals should avoid xanthomicrol-containing supplements entirely due to the complete absence of reproductive safety data and the theoretical risk posed by antiangiogenic compounds to fetal vascularization. Individuals on cancer treatment protocols should consult an oncologist before use.

## Scientific Research

The research on xanthomicrol is currently limited to preclinical in vitro and in vivo animal studies; no human clinical trials or meta-analyses are available. Key studies include its effects on mouse melanoma models and various cancer cell lines.

## Historical & Cultural Context

There are no detailed accounts of traditional or historical uses of xanthomicrol specifically. It is recognized as a natural component of Dracocephalum kotschyi, a medicinal herb.

## Synergistic Combinations

Curcumin, Resveratrol, Quercetin, EGCG, Sulforaphane

## Frequently Asked Questions

### What is xanthomicrol and where does it come from?

Xanthomicrol is a polymethoxylated flavonoid belonging to the flavone subclass, naturally occurring in aromatic herbs such as Satureja thymbra, Satureja montana, and Calamintha incana. It is structurally characterized by multiple methoxy substituents on its flavone backbone, which are believed to contribute to its enhanced bioactivity and lipophilicity compared to less-methylated flavonoids.

### How does xanthomicrol inhibit angiogenesis?

Xanthomicrol inhibits the formation of new blood vessels by suppressing VEGF-mediated endothelial cell signaling, reducing endothelial proliferation and capillary tube formation in experimental models. In vivo animal studies showed its antiangiogenic potency was comparable to thalidomide, a drug used clinically for its antiangiogenic properties in multiple myeloma. This mechanism is particularly relevant to tumor growth inhibition, as solid tumors depend on neovascularization for oxygen and nutrient supply.

### Is xanthomicrol safe to take as a supplement?

There are currently no human clinical trials, established dosing guidelines, or formal toxicology assessments for xanthomicrol as a dietary supplement. All existing data come from in vitro cell culture and in vivo animal studies, making it impossible to confirm a safe or effective dose for humans. Until rigorous safety and pharmacokinetic studies are completed, taking xanthomicrol supplements carries unknown risks.

### Does xanthomicrol interact with any medications?

No formal drug interaction studies have been conducted for xanthomicrol in humans. Based on its mechanisms, theoretical interactions are possible with antiangiogenic drugs like bevacizumab or sunitinib, chemotherapy agents that affect cell cycle progression, and potentially anticoagulants given the vascular-modulating activity seen in preclinical models. Anyone currently taking prescription medications, especially oncology treatments, should consult a healthcare provider before using any supplement containing xanthomicrol.

### What does research show about xanthomicrol's effectiveness against cancer cell types?

Clinical and preclinical studies demonstrate that xanthomicrol exhibits cytotoxic effects across multiple cancer models, including HCT116 colon cancer cells (where it induces apoptosis and G2/M cell cycle arrest), HeLa cervical cancer cells, and triple-negative breast cancer models. The compound shows selective toxicity toward cancer cells while demonstrating lower cytotoxicity in normal fibroblasts, suggesting potential for targeted cancer therapeutics. Research also indicates xanthomicrol suppresses cancer cell migration and invasion pathways, contributing to its antiproliferative mechanisms.

### Who should avoid xanthomicrol supplementation based on current evidence?

Individuals undergoing active cancer treatment should consult oncologists before using xanthomicrol, as its apoptosis-inducing and cell cycle-arresting properties may interact with conventional chemotherapy or immunotherapy protocols. Pregnant and nursing women should avoid xanthomicrol due to insufficient safety data and its potent effects on cell proliferation and apoptosis. Those with bleeding disorders or taking anticoagulant medications warrant medical supervision, as angiogenesis inhibition can affect vascular function and wound healing.

### How does xanthomicrol's mechanism compare to other angiogenesis inhibitors used in research?

Xanthomicrol demonstrates antiangiogenic potency comparable to thalidomide, a well-known anti-angiogenic agent, making it a notable candidate for further development in vascular biology research. Unlike some broad-spectrum angiogenesis inhibitors, xanthomicrol shows selectivity for cancer cells while sparing normal fibroblasts, potentially reducing off-target effects. The compound's dual action—inhibiting both angiogenesis and directly inducing cancer cell apoptosis—distinguishes it from single-mechanism inhibitors studied in oncology.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*